Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acelyrin Inc (NQ: SLRN )

4.880 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3
Open 4.880
Bid (Size) 4.250 (1)
Ask (Size) 5.520 (18)
Prev. Close 4.880
Today's Range 4.880 - 4.880
52wk Range 4.140 - 29.88
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Announces Leadership Transition
From ACELYRIN, INC.
Via GlobeNewswire

Performance

YTD
-38.54%
-38.54%
1 Month
-17.98%
-17.98%
3 Month
-40.42%
-40.42%
6 Month
-40.63%
-40.63%
1 Year
-80.42%
-80.42%

More News

Read More
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
From ACELYRIN, INC.
Via GlobeNewswire
SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023
Via InvestorPlace
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
From ACELYRIN, INC.
Via GlobeNewswire
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
From Avalo Therapeutics
Via GlobeNewswire
Investors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients
Via Benzinga
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
From ACELYRIN, INC.
Via GlobeNewswire
Acelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis Study
Via Benzinga
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
From ACELYRIN, INC.
Via GlobeNewswire
Acelyrin (SLRN) Investor Update: Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
SLRN DEADLINE TOMORROW: ROSEN, A LEADING NATIONAL FIRM, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
SLRN DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
SLRN DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ACELYRIN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Acelyrin, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SLRN IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action SLRN
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
SLRN DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ACELYRIN, INC. Investors with Losses in Excess of $100k to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Acelyrin, and Beauty Health and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SLRN IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ACELYRIN SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options
From Faruqi & Faruqi LLP
Via GlobeNewswire
Final Deadline Approaching for SLRN Investors: Kessler Topaz Meltzer & Check, LLP Reminds Acelyrin, Inc. (SLRN) Investors of Class Action Lawsuit Deadline on January 16, 2024
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SLRN
From The Rosen Law Firm PA
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.